{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T05:26:25Z","timestamp":1772861185758,"version":"3.50.1"},"reference-count":111,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2024,3,3]]},"DOI":"10.1080\/13543784.2024.2319317","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T16:51:42Z","timestamp":1707929502000},"page":"229-242","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials"],"prefix":"10.1080","volume":"33","author":[{"given":"Dominik","family":"Kiem","sequence":"first","affiliation":[{"name":"Paracelsus Medical University","place":["Salzburg, Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8263-6288","authenticated-orcid":false,"given":"Matthias","family":"Ocker","sequence":"additional","affiliation":[{"name":"Charit\u00e9 University Medicine Berlin","place":["Berlin, Germany"]},{"name":"EO Translational Insights Consulting GmbH","place":["Berlin, Germany"]},{"name":"Tacalyx GmbH","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[{"name":"Paracelsus Medical University","place":["Salzburg, Austria"]},{"name":"Cancer Cluster Salzburg","place":["Salzburg, Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9155-5762","authenticated-orcid":false,"given":"Daniel","family":"Neureiter","sequence":"additional","affiliation":[{"name":"Cancer Cluster Salzburg","place":["Salzburg, Austria"]},{"name":"Paracelsus Medical University, University Hospital Salzburg (SALK)","place":["Salzburg, Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Melchardt","sequence":"additional","affiliation":[{"name":"Paracelsus Medical University","place":["Salzburg, Austria"]},{"name":"Cancer Cluster Salzburg","place":["Salzburg, Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.731798"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030738"},{"key":"e_1_3_5_5_1","unstructured":"Aleem A Shah H. Atezolizumab: treasure island. (FL): StatPearls Publishing; 2023 [cited 2023 Jan 9]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK567758\/#"},{"key":"e_1_3_5_6_1","unstructured":"Agency EM. Tecentriq (atezolizumab): an overview of tecentriq and why it is authorised in the EU. 2022 [cited 2023 Nov 19]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/tecentriq-epar-medicine-overview_en.pdf"},{"key":"e_1_3_5_7_1","unstructured":"Agency EM. Imfinzi (durvalumab): an overview of imfinzi and why it is authorised in the EU. 2022 [cited 2023 Nov 19]. EMA\/949093\/2022 EMEA\/H\/C\/004771. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/imfinzi-epar-medicine-overview_en.pdf"},{"key":"e_1_3_5_8_1","unstructured":"Agency EM Bavencio (avelumab) an overview of Bavencio and why it is authorised in the EU. 2022 [cited 2023 Nov 19]. EMA\/584705\/2022 EMEA\/H\/C\/004338]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/bavencio-epar-medicine-overview_en.pdf"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.09.020"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00473-5"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7642"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1265202"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1549"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00292-018-0507-x"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30406-5"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2022.104749"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0983"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12071073"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3054"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.006"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.001"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.09.006"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3384"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0149"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0593"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao4572"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.02.008"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02504-6"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1700"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-022-00030-4"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku1003"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1146934"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001631"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13989"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2023.100884"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004949"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092638"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.05.019"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2021-002803"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006654"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202102500"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.05.024"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0304"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.871085"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101184"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00226-1"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.07.072"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100467"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22975-7"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.754"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-5525"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101305"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1091-2"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01723-1"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1449"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3548"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1943180"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.05.003"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12520"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1271"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep15659"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3716"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.04.011"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08637-9"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01794"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1222861110"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-2129"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003464"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.2529"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02679-5"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-CT513"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102288"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4597"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1272"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004322"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.10.155"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24767-5"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002131"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e14511"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.2004661"},{"issue":"2","key":"e_1_3_5_82_1","first-page":"A764","article-title":"732\u2005First-in-human trial to evaluate safety, PK\/PD and initial clinical activity of NM21\u20131480, an affinity-balanced PD-L1x4\u20131BBxHSA trispecific antibody: results of phase 1 dose escalation","volume":"10","author":"Jason L","year":"2022","unstructured":"Jason L, Melissa J, Shirish G, et al. 732\u2005First-in-human trial to evaluate safety, PK\/PD and initial clinical activity of NM21\u20131480, an affinity-balanced PD-L1x4\u20131BBxHSA trispecific antibody: results of phase 1 dose escalation. J Immunother Cancer. 2022;10(Suppl 2):A764.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2958"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2762"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002428"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04193-5"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13146"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01045-x"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01363-8"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005543"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan5488"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000433"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001395"},{"issue":"9","key":"e_1_3_5_94_1","first-page":"e1292","article-title":"Phase I study of the bifunctional fusion protein bintrafusp Alfa in Asian patients with advanced solid tumors, including a hepatocellular carcinoma safety-assessment cohort","volume":"25","author":"Doi T","year":"2020","unstructured":"Doi T, Fujiwara Y, Koyama T, et al. Phase I study of the bifunctional fusion protein bintrafusp Alfa in Asian patients with advanced solid tumors, including a hepatocellular carcinoma safety-assessment cohort. Oncology. 2020 Sep;25(9):e1292\u2013e1302.","journal-title":"Oncology"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.003"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00809-2"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00810-9"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000664"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac254"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000564"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02605-9"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0346"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12244"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.2512"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00521-4"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-021-00800-2"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2022.015"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.925985"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002500"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.02.015"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175"},{"issue":"18","key":"e_1_3_5_113_1","first-page":"1722","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau P","year":"2022","unstructured":"Moreau P, Girgis S, Goldberg JD. Teclistamab in Relapsed or Refractory Multiple Myeloma. Reply N Engl J Med. 2022 Nov 03;387(18):1722\u20131723.","journal-title":"Reply N Engl J Med"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2024.2319317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T07:09:09Z","timestamp":1738220949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2024.2319317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":111,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,3]]}},"alternative-id":["10.1080\/13543784.2024.2319317"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2024.2319317","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}